General Information of the Drug (ID: M6APDG01343)
Name
Dapsone
Synonyms
Dapson; Dapsonum; Diaphenylsulfon; Diaphenylsulfone; Diaphenylsulphon; Diaphenylsulphone; Diphenasone; Diphone; Disulone; Dubronax; Dumitone; Eporal; Metabolite C; Novophone; Sulfadione; Sulfona; Sulfona-MAE; Sulphadione; Sulphonyldianiline; Aczone; Avlosulfon; Avlosulfone; Avlosulphone; Bis(4-aminophenyl) sulfone; Croysulfone; Croysulphone; Sumicure S; Tarimyl; Udolac; dapsone; p-Aminophenyl sulfone; 4,4'-Diaminodiphenyl sulfone; 4,4'-Diaminodiphenylsulfone; 4,4'-Sulfonyldianiline; 4-Aminophenyl sulfone; 80-08-0; DADPS
    Click to Show/Hide
Status
Approved
Structure
Formula
C12H12N2O2S
InChI
1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2
InChIKey
MQJKPEGWNLWLTK-UHFFFAOYSA-N
PubChem CID
2955
INTEDE Drug ID
DR0415
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cytochrome P450 2C8 (CYP2C8)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Dapsone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Dapsone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Dapsone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Dapsone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Dapsone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dapsone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
YTH domain-containing protein 2 (YTHDC2)
In total 1 mechanisms lead to this potential drug response
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Dapsone. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Dapsone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
Prostaglandin G/H synthase 2 (COX-2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Dapsone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dapsone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). [3], [4]
References
Ref 1 Methylation of adenosine at the N(6) position post-transcriptionally regulates hepatic P450s expression. Biochem Pharmacol. 2020 Jan;171:113697. doi: 10.1016/j.bcp.2019.113697. Epub 2019 Nov 7.
Ref 2 CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
Ref 3 METTL3 promotes experimental osteoarthritis development by regulating inflammatory response and apoptosis in chondrocyte. Biochem Biophys Res Commun. 2019 Aug 13;516(1):22-27. doi: 10.1016/j.bbrc.2019.05.168. Epub 2019 Jun 8.
Ref 4 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. doi: 10.2174/092986709789057635. Epub 2009 Sep 1.